The Role of GLP-1RAs in Depression among Patients with Metabolic Conditions

The regular co-occurrence of depression with metabolic syndrome (Mets) results in complicated treatment circumstances and raises cardiovascular diseases and type 2 diabetes risks. GLP-1RAs demonstrate potential as an innovative treatment for depression because they have both anti-inflammatory properties and neuroprotective capabilities. This evaluation examines the advantages and results of GLP-1RAs in treatment effectiveness compared to CBT among patients with MetS. The research used PubMed and CINAHL databases to find peer-reviewed studies from 2021 until 2025. The research included the search terms “GLP-1 receptor agonists” together with “depression,” “metabolic syndrome,” and “cognitive behavioral therapy,” among other relevant terms. Applying GLP-1RAs generates successful depressive symptom reduction in 55-60% of MetS patients, above what CBT achieves in 40% while simultaneously improving HbA1c levels. The study presents several constraints due to small participant numbers, high financial requirements, and regulatory restrictions against extended use. Randomized controlled trials must take place on a large scale before determining the effectiveness and safety of using GLP-1RAs as dual therapeutic agents. Future studies should determine the right dosage combination of GLP-1RAs with CBT to improve patient results. Keywords: Metabolic syndrome, Depression, GLP-1RAs, Neuroinflammation, CBT